Clinical outcomes of platinum-based chemotherapy plus cetuximab for recurrent or metastatic squamous cell carcinoma of the head and neck: comparison between platinum-sensitive and platinum-resistant patients

Acta Oto-laryngologica
Hiroki SatoKouki Miura

Abstract

Combination therapy consisting of a platinum agent, 5-fluorouracil and cetuximab (EXTREME regimen) is recommended for recurrent or metastatic squamous cell carcinoma of the head and neck (R/M-SCCHN). However, it is advisable to use platinum-free regimens as first-line therapy in patients resistant to platinum agents. There has been no report comparing EXTREME regimen outcomes between platinum-resistant and platinum-sensitive patients. We conducted this study to examine the outcomes of the EXTREME regimen as first-line therapy in patients with R/M-SCCHN and a history of platinum agent use and assess whether the EXTREME regimen outcomes differ between platinum-resistant and platinum-sensitive patients. The study included 32 patients with R/M-SCCHN who received the EXTREME regimen as first-line therapy. Patients with recurrence or metastasis within 6 months after cisplatin administration were considered platinum-resistant and those with no recurrence or metastasis within 6 months were considered platinum-sensitive. 17 patients were platinum-resistant and 15 patients were platinum-sensitive. The median survival durations were 10.6 and 19.9 months in the platinum-resistant and platinum-sensitive patients, respectively, and the progn...Continue Reading

References

Feb 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C JacobsL Schacter
Jan 1, 1995·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J P Armand, C Couteau
Jul 17, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A N GordonA J Lacave
May 7, 2004·The New England Journal of Medicine·Jay S CooperUNKNOWN Radiation Therapy Oncology Group 9501/Intergroup
May 7, 2004·The New England Journal of Medicine·Jacques BernierUNKNOWN European Organization for Research and Treatment of Cancer Trial 22931
Oct 26, 2007·The New England Journal of Medicine·Jan B VermorkenUNKNOWN EORTC 24971/TAX 323 Study Group
Oct 26, 2007·The New England Journal of Medicine·Marshall R PosnerUNKNOWN TAX 324 Study Group
Sep 12, 2008·The New England Journal of Medicine·Jan B VermorkenRicardo Hitt
Mar 26, 2009·Journal of the National Cancer Institute·Yoann PointreauGilles Calais
May 19, 2009·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Jean-Pierre PignonUNKNOWN MACH-NC Collaborative Group
Oct 11, 2016·The New England Journal of Medicine·Robert L FerrisMaura L Gillison

❮ Previous
Next ❯

Citations

Apr 4, 2019·PharmacoEconomics·Celia Sabry-GrantAlexander Diamantopoulos

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Squamous Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.